Evidence map›Paper›PMID 36210416›Full record

ArticleBulletin of experimental biology and medicine2022

Comparative Analysis of the Pharmacological Activity of Bis(3,5-di-Tert-Butyl-4-Hydroxyphenylthiolate)Dimethylol in Different Modes of Administration on a Mouse Model of Melanoma B16 Tumor Growth.

M A Dodokhova, I M Kotieva, A V Safronenko, M S Alkhusein-Kulyaginova, N V Sukhorukova, V M Kotieva, E M Kotieva, S I Starostin, D B Shpakovsky, E A Nikitin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

M A DodokhovaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia. dodohova@mail.ru.
I M KotievaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
A V SafronenkoRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
M S Alkhusein-KulyaginovaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
N V SukhorukovaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
V M KotievaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
E M KotievaRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
S I StarostinRostov State Medical University, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia.
D B ShpakovskyFaculty of Chemistry, M. V. Lomonosov Moscow State University, Moscow, Russia.
E A NikitinFaculty of Chemistry, M. V. Lomonosov Moscow State University, Moscow, Russia.
E R MilaevaFaculty of Chemistry, M. V. Lomonosov Moscow State University, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed a comparative analysis of the pharmacological activity of the hybrid organotin compound bis(3,5-di-tert-butyl-4-hydroxyphenylthiolate)dimethylol (Me-3) administered in different modes to mice with transplanted melanoma B16 to identify the most effective dosage regimen. Three modes of administration were used: preventive (before transplantation of tumor cells), classical according to Z. P. Sof'ina (48 h after transplantation of tumor cells), and delayed (7 days after transplantation of tumor cells, after formation of nodules of the primary tumor node). Compound Me-3 was administered at a total dose of 375 mg/kg intraperitoneally once a day for 5 days. The classical mode of administration was identified as the most effective, which indicates the preventive antimetastatic activity of Me-3 on the model of the transplanted mouse tumor melanoma B16.

Indexed as

Lung NeoplasmsMelanomaMelanoma, ExperimentalAnimalsDisease Models, AnimalMiceMice, Inbred C57BLmelanoma B16metastasismodes of administrationsorganotin compounds

Identifiers

PMID36210416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.